肺結核患者の白血球機能に関する研究 第二編 肺結核患者の白血球機能に及ぼす各種薬剤併用療法の影響に就いて

In the successive administration of combination of such drugs as SM-PAS, PAS-INH, SM-PAS-INH, and PZA-INH to 23 patients with pulmonary tuberculosis, the author investigated the effects of these combination therapies on the leucocyte count and on the neutrophil function in the course of treatment, and obtained the following results: 1. Leucocyte count: The leucocyte count decreases up to the 5 th clay in the case of SM-PAS-INH combination; up to the 10 th day in the SM-PAS or PZA-INH combination; and up to the 20 th day in the PAS-INH combination, and thereafter it gradually increases in everyone of these combinations, until finally losing the effectiveness of the combination drug therapy by the end of one-month treatment. There on the leucocyte count is controlled by the conditions of disease. 2. Various Icucocytes: In every combination neutrophils decrease up to the 5 th-20 th day; monocytes up to the 10 th-20 th day; and lymphocytes up to the 5 th-10 th day, but in eosinophils only an increase has been observed, After one month various leucocytes change in number according to the changes in the condition of disease itself rather than to the effect of drugs. 3. Leucocyte function: The influence of each combination therapy appears most effectively between the 10 th and 20 th days; and in the combinations of Styl-PAS and PAS-INH marked acceleration of the function is brough about; while the combinations of SM-PAS-INH and PZA-INH acts inhibitorily on the function. One month after the initiation of the combination treatment and thereafter the function is influenced secondarily by changes in the conditions of a patient due to drugs administered rather than by the effect of drugs itself. 4. In other words, admitting marked clinical effects of the combination thbrapy of anti-tuberculous agents, it is important to bear in mind a possibility of some unfavorable effects of the combination therapy on the leucocyte function.

岡山医学会